昂利康：未来改良型新药和创新药将成为公司研发的重点

Core Viewpoint - The company, Anglikang, is shifting its focus towards innovative drugs and improved new drugs in its research and development strategy, with a significant increase in investment expected for innovative drug development in the coming years [2] Group 1: R&D Strategy - The company plans to prioritize innovative drugs and improved new drugs in its overall strategy, with innovative drug R&D expenses expected to surpass those for improved new drugs in the future [2] - Current innovative drug pipeline includes two main projects: ALK-N001/QHL-1618 targeting chemotherapy and ALK-N002/IMD-1005 focusing on immunotherapy [2] - The company is also exploring opportunities in other therapeutic areas to enhance its product pipeline structure [2] Group 2: Current Projects - The improved new drug ALKA016-1 has completed registration application, while NHKC-1 and BM2216 sustained-release tablets are currently in clinical stages [2] - Future selection of improved new drugs will rely on existing technology platforms such as compound, controlled-release, transdermal, and complex injection formulations to explore new pipeline products [2]